Core Viewpoint - Guardant Health is a significant player in precision oncology, focusing on blood tests for cancer detection and treatment, with recent positive ratings from analysts and mixed investor actions [1][5]. Investment Ratings - Raymond James upgraded Guardant Health to "Outperform" with a price target increase from $115 to $129, reflecting confidence in the company's future performance [1][5]. Investor Actions - Granite Investment Partners LLC reduced its stake in Guardant Health by 52.1%, now holding 185,301 shares valued at approximately $11.6 million, contrasting with other investors [2][5]. - Norges Bank acquired a new stake in Guardant Health worth around $64.1 million during the second quarter [3]. - Franklin Resources Inc. increased its investment by 78.2%, now holding 2,319,947 shares valued at $120.7 million after purchasing an additional 1,018,144 shares [3]. - Invesco Ltd. expanded its holdings by 27.3% during the undefined quarter [3]. Stock Performance - The current stock price for Guardant Health is approximately $100.42, reflecting a decrease of about 2.60%, with fluctuations between a low of $100.29 and a high of $103.58 [4]. - Over the past year, the stock has reached a high of $120.74 and a low of $34.88, with a market capitalization of approximately $13.04 billion and a trading volume of around 274,345 shares [4].

US biotech company Guardant Health (Nasdaq: GH) has acquired Israeli precise liquid biopsy company MetaSight Diagnostics for an immediate payment of $59 million and an additional $90 million in milestone payments. The acquisition was revealed in Guardant Health’s fourth quarter results. The milestone payments include receiving regulatory approvals and sales thresholds. The company has developed tests for accurate early diagnosis of cancer that could cost only a few dollars. MetaSight was founded by Prof. ...

Adjusted EBITDA loss narrowed to $64.9 million in Q4 from $78.4 million in the prior-year quarter. For the full year, adjusted EBITDA loss improved to $220.9 million versus $257.5 million in 2024.Management attributed the performance to “broad-based growth” across oncology, screening, and the biopharma and data segment. The company reported non-GAAP gross margin of 66% in Q4, up from 63% a year earlier, and 66% for the full year, up from 62% in 2024.Guardant said total revenue increased 39% year over year t ...

Guardant Health (GH) reported $281.27 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 39.4%. EPS of -$0.50 for the same period compares to -$0.62 a year ago.The reported revenue represents a surprise of +0.47% over the Zacks Consensus Estimate of $279.96 million. With the consensus EPS estimate being -$0.42, the EPS surprise was -18.12%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

Guardant Health (NasdaqGS:GH) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAmirAli Talasaz - Co-CEOCasey Woodring - Vice President of Equity ResearchDaniel Markowitz - VPEric Hershey - VP of Investor RelationsHelmy Eltoukhy - Co-CEOJack Meehan - Partner- Life Science Tools & DiagnosticsLuke Sergott - Director of Healthcare Equity ResearchMike Bell - CFOConference Call ParticipantsAndrew Brackmann - Research AnalystBill Bonello - Senior Research AnalystDan Leonard - Managing Direct ...

Guardant Health (NasdaqGS:GH) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAmirAli Talasaz - Co-CEOCasey Woodring - Vice President of Equity ResearchDaniel Markowitz - VPEric Hershey - VP of Investor RelationsHelmy Eltoukhy - Co-CEOJack Meehan - Partner- Life Science Tools & DiagnosticsLuke Sergott - Director of Healthcare Equity ResearchMichael Ryskin - Managing DirectorMike Bell - CFOConference Call ParticipantsAndrew Brackmann - Research AnalystBill Bonello - Senior Research An ...

Guardant Health (NasdaqGS:GH) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker15Good afternoon. Thank you for attending the Guardant Health Q4 2025 earnings call. My name is Cameron, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference over to your host, Eric Hers ...

Financial Performance - The company has incurred significant losses since inception and may continue to do so, with uncertainty about achieving and maintaining profitability[22]. - The reimbursement landscape is variable and unpredictable, which may lead to revenue adjustments and impact future financial guidance[74]. - The company anticipates ongoing proposals at federal and state levels to reduce healthcare costs and improve coverage, which may impact pricing and reimbursement for its tests[162]. Product Offerings - The Guardant360 CDx test is a 74-gene liquid biopsy test approved by the FDA, providing tumor mutation profiling for cancer patients, and is the market leader in its category[33]. - The Shield blood test is the first FDA-approved blood test for primary colorectal cancer screening, meeting Medicare coverage requirements, and included in the National Comprehensive Cancer Network guidelines[25]. - The company expects to expand its Shield platform into lung cancer screening and multi-cancer detection (MCD), with the Shield MCD test receiving Breakthrough Device designation from the FDA[41]. - The Guardant Reveal test has been expanded to include late-stage therapy response monitoring, leveraging proprietary technology to predict therapy response across all classes[35]. - The Guardant360 Liquid test measures over 740 genes and supports guideline-recommended biomarkers, providing advanced cancer patients with personalized therapy options[34]. - GuardantINFINITY test provides a comprehensive molecular profile of tumors with genotyping coverage of over 800 genes, enhancing biomarker discovery and clinical research[43]. - GuardantOMNI test covers 500 genes and has achieved superior sensitivity for detecting clinically actionable biomarkers compared to the Guardant360 Liquid test[45]. - GuardantINFORM database offers longitudinal biological insights into tumor evolution and clinical outcomes, supporting drug discovery and clinical research[46]. - The Smart Platform enhances research and development efficiencies, driving faster turnaround times and cost savings while providing industry-leading sensitivity[48]. Market Expansion and Partnerships - The company aims to strengthen relationships with biopharmaceutical companies to enhance revenue prospects and support product adoption[27]. - The company is focused on expanding global market access through strategic partnerships and investments in clinical utility[30]. - The company has expanded its international commercial efforts, establishing partnerships in Europe and Asia, including a CE mark for the Guardant360 CDx test[57][58]. - In Japan, the Guardant360 CDx test received national reimbursement approval for patients with advanced or metastatic solid tumor cancers[58]. - The company is actively working to expand coverage among commercial payers, which may lead to increased average revenue per test performed[64][65]. Regulatory Environment - The company currently markets its Guardant360 CDx test and the Shield test under an approved PMA, which is more demanding than the 510(k) premarket notification process[110]. - The PMA process generally takes between one and three years, but may take significantly longer depending on the complexity of the application[112]. - The FDA has 180 days to review a filed PMA, although the review often occurs over a longer period[112]. - The FDA may require post-approval studies or post-market surveillance as a condition of PMA approval to ensure ongoing safety and effectiveness[114]. - The 510(k) clearance process requires manufacturers to demonstrate that a device is "substantially equivalent" to a legally marketed predicate device[104]. - The FDA is required to complete its review of a 510(k) notification within 90 days, but clearance often takes longer[105]. - Class III devices, which pose the greatest risk, are subject to the more rigorous PMA process, which is generally more costly and time-consuming than the 510(k) process[103]. - The FDA may impose significant regulatory fines or penalties for failure to submit the requisite applications for device modifications[108]. - The FDA has proposed reforms to the 510(k) clearance process, which could include increased requirements for clinical data and a longer review period[109]. - The FDA's Breakthrough Devices Program aims to expedite the development and review of medical devices that provide more effective treatment for life-threatening conditions, allowing for more timely access to qualifying devices[120]. - The FDA may require simultaneous approval of companion diagnostics with therapeutic products, ensuring that diagnostics are adequately evaluated for safety and effectiveness[125]. - The EU's new In Vitro Diagnostic Regulation (IVDR) will strengthen market placement rules and enhance post-market surveillance, becoming applicable five years after its publication on May 26, 2022[139]. - Compliance with the essential requirements of the EU In Vitro Diagnostic Medical Devices Directive (IVDD) is necessary for obtaining the CE mark, which is required for marketing in the EU[132]. - The FDA has broad post-market regulatory enforcement powers, including unannounced inspections and potential sanctions for non-compliance, which can significantly impact operational costs[127]. - Legislative proposals regarding the regulation of laboratory developed tests (LDTs) may lead to increased regulatory requirements, potentially affecting the development and commercialization of new tests[122]. - The FDA's enforcement discretion generally applies to in vitro diagnostics used within a single laboratory, but future regulations could impose additional compliance costs[121]. - The EU medical device vigilance system mandates reporting of incidents and corrective actions to mitigate risks associated with in vitro diagnostic medical devices already on the market[134]. - The IVDR introduces a unique identification number for medical devices to improve traceability and facilitate efficient recalls in case of safety risks[139]. Employee and Workforce Diversity - As of December 31, 2025, the company had 2,506 employees, with 2,490 being full-time and approximately 2,278 located in the U.S.[163]. - The workforce was approximately 51% racially/ethnically diverse and 53% female as of December 31, 2025[165]. - For leadership positions, 32% self-identified as racially/ethnically diverse and 40% self-identified as women[165]. - Women held 33% of the independent director seats on the company's Board as of December 31, 2025[165]. - The company is committed to recruiting and retaining a diverse team aligned with its values[166]. Compliance and Legal Matters - The company is subject to federal fraud and abuse laws, including the Anti-Kickback Statute and the False Claims Act, which impose significant compliance obligations[150][154]. - In January 2022, the company received a civil investigative demand from the U.S. Attorney for the Northern District of California regarding billing for its genetic tests[157]. - The company is subject to evolving data privacy and security laws that govern the collection and protection of health-related personal information[158]. Financial Position - As of December 31, 2025, the company had cash, cash equivalents, restricted cash, and marketable debt securities totaling $1.3 billion[535]. - The majority of the company's revenue is generated in the United States, with an insignificant amount from foreign currencies as of December 31, 2025[536]. - A hypothetical 10% change in foreign currency exchange rates would not be material to the company's financial condition or results of operations[536]. - The company has not entered into any hedging arrangements regarding foreign currency risk to date[536]. - A hypothetical 100 basis point increase or decrease in interest rates would have resulted in an immaterial decline or increase in the fair value of the company's investments[535]. Employee Engagement and Compensation - Employee engagement surveys are regularly utilized to assess the effectiveness of employee development and compensation programs[166]. - The company offers a comprehensive total rewards package, including market-competitive pay, equity grants, and various insurance benefits[167]. - The compensation programs are evaluated with an independent consultant to ensure competitiveness and fairness across the workforce[166]. - The company maintains a focus on strategic alignment of talent and performance rewards while managing costs[167].

Conquering Cancer with Data Q4 2025 & Full Year 2025 Earnings Call February 19, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance ...

Core Viewpoint - Gamehost Inc. has announced a cash dividend of $0.05 (CDN) per common share for February 2026, which translates to an annualized rate of $0.60 (CDN) per share, to be paid on March 13, 2026, to shareholders of record on February 28, 2026 [1][2]. Company Overview - Gamehost Inc. is incorporated under the laws of Alberta, Canada, and operates various facilities including the Rivers Casino & Entertainment Centre in Ft. McMurray, the Great Northern Casino, Service Plus Inns & Suites, Encore Suites hotels, and the Deerfoot Inn & Casino in Calgary [3][4]. - The company's common shares are traded on the Toronto Stock Exchange (TSX) under the symbol GH [4].